Natco Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Natco Pharma Ltd reported a 15.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 36.5%.
• Its expenses for the quarter were up by 23.6% QoQ and down 13.9% YoY.
• The net profit increased 77.8% QoQ and decreased 33.7% YoY.
• The earnings per share (EPS) of Natco Pharma Ltd stood at 14.96 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Natco Pharma Ltd is a prominent player in the pharmaceutical industry, primarily known for its expertise in the development, manufacture, and marketing of generic pharmaceuticals. The company has established a strong presence in the oncology segment and is also involved in the production of other therapeutic products. Natco Pharma has been at the forefront of introducing cost-effective generic drugs, which significantly contribute to its revenue streams. The company operates in a highly competitive market, often influenced by regulatory changes and patent litigations, which can impact its operations. As of the latest period, there are no specific major developments noted in the financial data provided.

Revenue

In Q4FY26, Natco Pharma Ltd reported a total income of ₹816.90 crores, which represents a 15.8% increase compared to the previous quarter (Q3FY26) where the revenue was ₹705.40 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY25), there is a notable decrease of 36.5% from ₹1287.30 crores. This year-over-year decline in revenue suggests a reduction in sales or possibly changes in product mix or pricing. The sequential quarterly improvement indicates recent recovery or growth in sales or other income sources.

Profitability

The company's profit before tax (PBT) for Q4FY26 was ₹144.10 crores, indicating a decrease of 10.6% from the previous quarter's ₹161.10 crores. When compared to Q4FY25, PBT has decreased significantly by 71.5% from ₹505.90 crores. The tax component for Q4FY26 shows a credit of ₹89.20 crores, contrasting with a tax expense of ₹20.70 crores in the previous quarter and ₹99.90 crores in Q4FY25. Consequently, the profit after tax (PAT) for Q4FY26 stands at ₹269.00 crores, marking a 77.8% increase from Q3FY26's ₹151.30 crores, but a 33.7% decrease from ₹406.00 crores in Q4FY25. Earnings per share (EPS) for Q4FY26 is ₹14.96, reflecting a quarter-over-quarter increase of 76.8% from ₹8.46, yet a year-over-year decline of 34.1% from ₹22.70.

Operating Metrics

Natco Pharma Ltd's total expenses for Q4FY26 were ₹672.80 crores, which indicates a 23.6% increase from the previous quarter's expenses of ₹544.30 crores. Compared to Q4FY25, total expenses have decreased by 13.9% from ₹781.40 crores. This fluctuation in expenses may relate to changes in production costs, operational efficiency, or strategic investments. The profit margins observed through the profit after tax and earnings per share illustrate the company's ability to manage costs effectively despite variances in income. The tax dynamics, particularly the notable tax credit in Q4FY26, play a crucial role in the net profitability, impacting the financial metrics significantly for this quarter.